Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 17.33 SEK -4.31%
Market Cap: 809.2m SEK
Have any thoughts about
Moberg Pharma AB (publ)?
Write Note

Gross Margin
Moberg Pharma AB (publ)

65.2%
Current
33%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
65.2%
=
Gross Profit
3.2m
/
Revenue
4.9m

Gross Margin Across Competitors

Country SE
Market Cap 794.2m SEK
Gross Margin
65%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 749.7B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 372B USD
Gross Margin
69%
Country US
Market Cap 257.3B USD
Gross Margin
77%
Country CH
Market Cap 200.6B CHF
Gross Margin
73%
Country UK
Market Cap 162.5B GBP
Gross Margin
82%
Country CH
Market Cap 179.9B CHF
Gross Margin
75%
Country US
Market Cap 146B USD
Gross Margin
71%
No Stocks Found

Moberg Pharma AB (publ)
Glance View

Market Cap
794.2m SEK
Industry
Pharmaceuticals

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

MOB Intrinsic Value
0.6 SEK
Overvaluation 97%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
65.2%
=
Gross Profit
3.2m
/
Revenue
4.9m
What is the Gross Margin of Moberg Pharma AB (publ)?

Based on Moberg Pharma AB (publ)'s most recent financial statements, the company has Gross Margin of 65.2%.